News
FDA Clears Amygdala Neurosciences’ ANS-858 for Clinical Development
Amygdala Neurosciences is initially developing ANS-858 as a potential treatment for alcohol use disorder and other substance use disorders.
E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
Amygdala Neurosciences is initially developing ANS-858 as a potential treatment for alcohol use disorder and other substance use disorders.
HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
